India has rapidly become the third-largest global destination for clinical trials, registering over 18,000 new trials in 2024—a 50% increase from the previous year. This surge is driven by India’s diverse patient population, strong government initiatives like the National Biopharma Mission, and the rise of Global Capability Centers (GCCs) established by leading pharma companies such as Bristol Myers Squibb, Novartis, and Bayer. With robust infrastructure and talent, India is positioning itself as a trusted partner for global pharmaceutical innovation.
Key Highlights:
- 📈 50% growth in clinical trial registrations in 2024.
- 🌐 India now ranks third globally for clinical trials.
- 🏥 Strong support from government-backed initiatives and research networks.
- 🤝 Increasing global collaborations with pharma leaders.
- 👩⚕️ India’s diverse population offers unique advantages for multi-ethnic trials.
Our Commentary:
- At Anveta Therapeutics , we believe this momentum reflects the power of collaboration in driving innovation. India’s rise as a global hub for clinical trials shows how partnerships between startups, government, and international organizations can unlock breakthroughs that benefit the world.
- Our collaboration model is designed to connect innovators, researchers, and industry leaders, ensuring that India’s strengths in diversity, scale, and talent are fully leveraged. By aligning with this ecosystem, we aim to contribute to the next wave of global healthcare solutions emerging from India.